Literature DB >> 16141625

A nuclear receptor-mediated choleretic action of fibrates is associated with enhanced canalicular membrane fluidity and transporter activity mediating bile acid-independent bile secretion.

Tomoji Nishioka1, Hideyuki Hyogo, Yoshihiro Numata, Atsushi Yamaguchi, Toshiya Kobuke, Daisuke Komichi, Michihiro Nonaka, Motoki Inoue, Yoshitaka Nabeshima, Mami Ogi, Keiko Iwamoto, Tomokazu Ishitobi, Takeyoshi Ajima, Kazuaki Chayama, Susumu Tazuma.   

Abstract

Fibrates are commonly used lipid-lowering agents that act via PPARalpha, a member of the nuclear hormone receptor superfamily. The mechanism(s) of fibrate-induced changes in the hepatic canalicular membrane and bile lipids are still unknown. Therefore, the aim of this study was to investigate the influence of fibrates on hepatic lipid metabolism and to assess the hepatocellular cytoprotective effect on hepatocyte canalicular membrane. Male ICR mice were fed standard chow with or without bezafibrate (100 mg/kg) for 6 days. The expression of canalicular membrane transporters (Mdr2 and Mrp2) was evaluated by RT-PCR and Western blotting. Canalicular membrane fluidity was also investigated. Canalicular membrane fluidity was markedly increased by fibrates. The expression of mdr 2 and mrp2 mRNA and protein showed a significant increase in fibrate-treated mice. These results suggested that fibrates improve liver function by enhancing bile secretion. The mechanism of the choleretic action of fibrate therapy might involve the enhancement of bile acid-independent bile secretion, since increased expression of Mdr2 and Mrp2 was found in fibrate-treated animals. These changes were very likely mediated by PPARalpha, and the increase of canalicular membrane fluidity may have been partly associated with enhancement of this transporter activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16141625     DOI: 10.5551/jat.12.211

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  8 in total

Review 1.  Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein).

Authors:  Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Pflugers Arch       Date:  2006-04-19       Impact factor: 3.657

2.  Alteration of canalicular transporters in a mouse model of total parenteral nutrition.

Authors:  Yuko Tazuke; Daniel H Teitelbaum
Journal:  J Pediatr Gastroenterol Nutr       Date:  2009-02       Impact factor: 2.839

Review 3.  Regulation of hepatic ABCC transporters by xenobiotics and in disease states.

Authors:  Xinsheng Gu; Jose E Manautou
Journal:  Drug Metab Rev       Date:  2010-08       Impact factor: 4.518

4.  Thyroid hormone receptor β1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice.

Authors:  Julien Gautherot; Thierry Claudel; Frans Cuperus; Claudia Daniela Fuchs; Thomas Falguières; Michael Trauner
Journal:  J Lipid Res       Date:  2018-06-12       Impact factor: 5.922

Review 5.  Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis.

Authors:  Yan Zhang; Sainan Li; Lei He; Fan Wang; Kan Chen; Jingjing Li; Tong Liu; Yuanyuan Zheng; Jianrong Wang; Wenxia Lu; Yuqing Zhou; Qin Yin; Yujing Xia; Yingqun Zhou; Jie Lu; Chuanyong Guo
Journal:  Drug Des Devel Ther       Date:  2015-05-25       Impact factor: 4.162

6.  Effects of three different fibrates on intrahepatic cholestasis experimentally induced in rats.

Authors:  Alaa El-Sisi; Sahar Hegazy; Eman El-Khateeb
Journal:  PPAR Res       Date:  2013-08-12       Impact factor: 4.964

7.  PPARα: A Master Regulator of Bilirubin Homeostasis.

Authors:  Cyril Bigo; Jenny Kaeding; Diala El Husseini; Iwona Rudkowska; Mélanie Verreault; Marie Claude Vohl; Olivier Barbier
Journal:  PPAR Res       Date:  2014-07-23       Impact factor: 4.964

8.  Alteration of MRP2 expression and the graft outcome after liver transplantation.

Authors:  Nam-Joon Yi; Joohyun Kim; YoungRok Choi; Heyoung Kim; Kyoung Bun Lee; Ja-June Jang; Jae Young Lee; Jeong Min Lee; Joon Koo Han; Kwang-Woong Lee; Kyung-Suk Suh
Journal:  Ann Surg Treat Res       Date:  2018-10-25       Impact factor: 1.859

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.